For research use only. Not for therapeutic Use.
TC-S 7005 is a Polo-like kinases (Plks) inhibitor with IC50s of 4 nM, 24 nM and 214 nM for Plk2, Plk3, and Plk1, respectively[1].
TC-S 7005 markedly induces myofibroblast differentiation and reduces fibroblast proliferation rates[2].
| Catalog Number | I010963 |
| CAS Number | 1082739-92-1 |
| Synonyms | 3-(1,3-benzodioxol-5-yl)-N-[(1S)-1-phenylethyl]-[1,2]oxazolo[5,4-c]pyridin-5-amine |
| Molecular Formula | C21H17N3O3 |
| Purity | ≥95% |
| InChI | InChI=1S/C21H17N3O3/c1-13(14-5-3-2-4-6-14)23-20-10-16-19(11-22-20)27-24-21(16)15-7-8-17-18(9-15)26-12-25-17/h2-11,13H,12H2,1H3,(H,22,23)/t13-/m0/s1 |
| InChIKey | DAAGOCSHXCDWDY-ZDUSSCGKSA-N |
| SMILES | CC(C1=CC=CC=C1)NC2=NC=C3C(=C2)C(=NO3)C4=CC5=C(C=C4)OCO5 |
| Reference | [1]. Hanan EJ, et al. Design and synthesis of 2-amino-isoxazolopyridines as Polo-like kinase inhibitors. Bioorg Med Chem Lett. 2008 Oct 1;18(19):5186-9. [2]. Stephan Reinhard Künzel, et al. Hypoxia-induced epigenetic silencing of polo-like kinase 2 promotes fibrosis in atrial fibrillation. bioRxiv 445098 |
